According to filings with the U.S. Securities and Exchange Commission, Ketryx is raising up to $37,499,973.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Ketryx
Ketryx transforms the product lifecycle of life science teams to deliver safer products, faster. Trusted by three of the worlds top five medical device manufacturers, its AI-native compliance platform overlays existing tools to automate documentation, create traceability, and accelerate release cycles without disrupting existing workflows. Ketryx AI Agents cut manual work by 90 percent and close compliance gaps, elevating speed and quality across the entire product lifecycle.

To learn more about Ketryx, visit https://www.ketryx.com/
Ketryx Linkedin Page: https://www.linkedin.com/company/ketryx/

Contact:
Erez Kaminski, President
781-523-2715
https://www.linkedin.com/in/erezkaminski/

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.